Nanocarriers For Drug Targeting

Preview this chapter:

Nanocarriers For Drug Targeting, Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815049787/chap3-1.gif

Drug targeting specific cells/tissues of the body without their becoming a part of the systemic circulation is a prominent area of research in drug delivery, with the main emphasis on improvement in formulation and development. Drug-targeting can improve the viability, lower/minimize the adverse/side effects, and can become cost-effective. Certain limitations like short circulating half-life, bioavailability issues, rapid metabolism and degradation, poor tissue distribution and penetration in the blood-brain barrier, intestinal absorption barriers, etc., are associated with the delivery of various therapeutic agents. Nanocarriers have arisen in the field of drug targeting with valuable delivery of drugs to site-specific/desired areas which is a significant therapeutic advantage since it keeps drugs from being conveyed to some unacceptable spots. Nanocarriers prevent the obstacles in clinical utilization of the therapeutic agents as they decrease the serious and critical side/adverse effects by targeted drug delivery and provide slow and sustained drug release. Nanocarriers bring new trust to drug targeting by upgrading the efficacy, defeating resistance, and minimizing toxicity. This chapter mainly focuses on the role and benefits of nanocarriers in drug-targeting and nanocarriers as prominent systems for targeting and delivering drugs to achieve maximum effects with improved therapeutic response. nbsp;